This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AMAG Pharmaceuticals Appoints Carol Satler, M.D., Ph.D. As Senior Vice President Of Medical And Scientific Affairs

Stocks in this article: AMAG

LEXINGTON, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the appointment of Carol Satler, M.D, Ph.D. as senior vice president of medical and scientific affairs. Dr. Satler brings to AMAG more than 25 years of healthcare experience, including 15 years in the global biopharmaceutical industry and 10 years in clinical practice. Prior to joining AMAG, Dr. Satler served in executive clinical development and medical affairs roles at Pfizer and Sanofi, as well as Forest Labs and Millenium.

"Carol has a long track record of success in medical affairs that will be extremely valuable to AMAG," said William Heiden, president and chief executive officer of AMAG. "Through her 15-year career in the pharmaceutical industry, Carol has formulated and implemented medical affairs strategies and life cycle management plans for several major commercial products each with annual revenues in excess of $1 billion across a variety of indications. This experience will be invaluable to us as we prepare for the potential launch of Feraheme® for the treatment of iron deficiency anemia in a broader patient population, as well as other areas of future opportunity."

Dr. Satler has broad-based industry experience and has led and managed teams across several therapeutics areas. She has held leadership roles in medical affairs, clinical research and development and administration both in the U.S. and globally. Dr. Satler has successfully formulated strategic clinical development plans, life cycle management and commercialization of products. Dr. Satler received her medical degree and Ph.D. from Case Western Reserve University, completed her internship and residency, and practiced medicine at the Boston Children's Hospital with a focus on cardiology.

Inducement Equity Awards

In connection with Dr. Satler's entry into her employment agreement, effective on the first day of employment, Dr. Satler will be granted (i) an option to purchase 45,000 shares of common stock and (ii) 15,000 restricted stock units. The option will have an exercise price equal to the closing price of AMAG's common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in four equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs